184
On June 1st, Marapharm Ventures Inc (CSE:MDM; OTC:MRPHF; FRA:2MO), announced that it has started cloning mother plants on the top 5 strains in the Nevada market, as it prepares to move to its permanent facility (with Phase III expansion at 300,000 square feet, said to be the largest production and cultivation facility in the state). The company has holdings in Washington State and California as well, and in British Columbia up here in Canada. It is Triple Organic Certified (Clean Green, Certified Kind, and DEM Pure) in the United States, and has two cultivation and one production license in Nevada. Recently they announced a non-brokered private placement and looks to raise up to $4.5 million at $0.50 a share (plus ½ warrants at $0.70 exercise price) to be used for further development of its projects in Nevada and other US states. At publication, its shares were trading at $0.45 on the open market, and has about 189 million fully diluted shares.
MPX Bioceutical Corporation (CSE: MPX; OTC: MPXEF) was a sub-feature in our February 2018 issue. In it you will find a very informative overview of the company along with a Q&A with Scott Boyes, CEO. To highlight its Nevada operations, it has recently signed a purchase agreement to acquire 99% interest in GreenMart of Nevada for $17.81 million USD (share based compensation of $8.31 million and secured promissory note of $9.5 million), which is a fully operational in cultivation and production, with up to 1.6 million grams per year cultivation capacity (currently at 85,000 grams) just in Nevada alone, which will leverage MPX’s award-winning, high-margin concentrates brand “Melting Point Extracts”. The company also plans on applying for at least one dispensary license in the state towards the end of 2018. For certain, MPX is much more than just Nevada, and for a detail look at the company, I urge you to review February’s issue of CannaInvestor Magazine.